Filtered By:
Condition: Thrombosis
Management: WHO
Procedure: Heart Transplant
This page shows you your search results in order of date.
Order by Relevance | Date
Total 3 results found since Jan 2013.
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1
1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2Humanitas Clinical and Research Center-IRCCS, Milan, Italy
3Humanitas University, Milan, Italy
4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Pathophysiologic role of ischemia reperfusion injury: a review
Publication date: Available online 19 June 2017 Source:Journal of Indian College of Cardiology Author(s): Vishal Kumar Vishwakarma, Prabhat Kumar Upadhyay, Jeetendra Kumar Gupta, Harlokesh Narayan Yadav Ischemic heart disease (IHD) is the major cause of morbidity and mortality all over the world. World health organization (WHO) in 2002 assumed that IHD may be the major leading cause of death by 2020. An estimated 17 million people died from cardiovascular diseases (CVS) globally. Of these deaths, 7 million people died by ischemia heart disease and 6.2 million by stroke. Ischemia is defined as an insufficient supply of the...
Source: Journal of Indian College of Cardiology - June 19, 2017 Category: Cardiology Source Type: research